碘化[1-环己基-3-（3-三甲氨丙基）碳二亚胺] | 132465-11-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 碘化[1-环己基-3-（3-三甲氨丙基）碳二亚胺]
• 中文别名: 3,4-二羟基-ALPHA-氰基肉桂酸肉桂基酯
• 英文名称: cinnamyl-3,4-dihydroxy-α-cyanocinnamate
• 英文别名: CDC；Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate；[(E)-3-phenylprop-2-enyl] (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate
• CAS: 132465-11-3
• 化学式: C₁₉H₁₅NO₄
• 分子量: 321.332
• InChiKey: XGHYFEJMJXGPGN-UYHGDYIZSA-N

物化性质

• 沸点：
  583.9±50.0 °C(Predicted)
• 密度：
  1.326±0.06 g/cm3(Predicted)
• 溶解度：
  在DMSO中的溶解度≥15mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  9

文献信息

• PAIN RELIEF COMPOUNDS
  申请人：ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND

  公开号：US20150038466A1

  公开（公告）日：2015-02-05

  The present invention relates to the use of compounds for the treatment or prevention of pain in mammals, in particularly in human beings, and also to a process for preparing these compounds.

  本发明涉及使用化合物治疗或预防哺乳动物（尤其是人类）的疼痛，并且涉及一种制备这些化合物的方法。
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DRUG ADDICTION<br/>[FR] MÉTHODES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE LA TOXICOMANIE
  申请人：UNIV NICE SOPHIA ANTIPOLIS

  公开号：WO2016026978A1

  公开（公告）日：2016-02-25

  The present invention relates to methods and pharmaceutical compositions for treating drug addiction, preferably alcoholism, ecstasy addiction or cocaine addiction, in a subject in need thereof. In particular, the present invention relates to a method for treating drug addiction in a subject in need thereof comprising administering the subject with a TREK agonist, particularly a TREK1 and/or TREK2 agonist.

  本发明涉及用于治疗药物成瘾的方法和药物组合物，优选用于治疗酒精中毒、摇头丸成瘾或可卡因成瘾的主体。具体来说，本发明涉及一种治疗药物成瘾的方法，包括向需要的主体施用TREK激动剂，特别是TREK1和/或TREK2激动剂。
• Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway
  申请人：O'Connor James Patrick

  公开号：US20110105959A1

  公开（公告）日：2011-05-05

  Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods rely on in vivo or ex vivo modulation of an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors, leukotriene A4 hydrolase inhibitors, and/or leukotriene B4 receptor antagonists. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.

  公开了促进成骨作用以加速或增强骨折愈合、治疗骨缺陷和增强骨形成的方法。这些方法依赖于体内或体外调节花生四烯酸代谢或信号通路的总体，特别是利用5-脂氧合酶抑制剂、白三烯A4水解酶抑制剂和/或白三烯B4受体拮抗剂。这些分子可以单独或与一个或多个抑制骨吸收、调节从骨中钙吸收、增强骨积累、增强骨形成、诱导骨形成、抑制微生物生长、减少炎症和/或减轻疼痛的剂量联合使用。
• Aldosterone blocker therapy to prevent or treat inflammation-related disorders
  申请人：Pharmacia Corporation

  公开号：US20040037806A1

  公开（公告）日：2004-02-26

  A method of preventing or treating an inflammation-related disorder such as myocarditis, cardiomyopathy, vasculitis, and Behcet's disease in a subject, comprising treating the subject with a therapeutically-effective amount of an aldosterone blocker sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation or cardiac remodeling in the subject.

  一种预防或治疗与炎症相关的疾病，如心肌炎、心肌病、血管炎和Behcet病的方法，包括使用治疗剂量的醛固酮受体阻滞剂来治疗受试者，该治疗剂量足以改变与受试者中炎症或心脏重塑调节相关的一个或多个表达产物的表达。
• Caffeic acid derivatives and pharmaceutical compositions containing the same
  申请人：SUNTORY LIMITED

  公开号：EP0475214A1

  公开（公告）日：1992-03-18

  Described are caffeic acid derivatives represented by the following formula: wherein either one of R¹ and R² is a hydrogen atom, a C₁-C₆ alkyl group, a group -CO₂R⁴, or a group -CONR⁵R⁶, R⁴, R⁵ and R⁶ being either a hydrogen atom or a particular group, and the other is the group -CO₂R⁴ or the group -CONR⁵R⁶, or R¹ and R² are coupled together to represent a 5-membered ring so formed, Y represents a particular group or atom, X represents a substituted or unsubstituted C₆-C₁₀ aryl, C₇-C₁₂ aralkyl, heterocyclic or heterocyclic ring-alkyl group, m and n stand for particular integers, and R₃ represents a hydrogen atom, a hydroxyl group, a group -OCO₂R⁷, R⁷ being a hydrogen atom or a particular group, or a group -OCONR⁸R⁹, R⁸ representing a C₁-C₆ alkyl group and R⁹ representing a hydrogen atom or a C₁-C₆ alkyl group, and pharmaceutically acceptable salts thereof. Therapeutic agents containing the derivatives or salts are effective for diseases of the circulatory system.

  所述的咖啡酸衍生物由下式表示： 其中R¹和R²之一是氢原子、C₁-C₆烷基、基团-CO₂R⁴或基团-CONR⁵R⁶，R⁴、R⁵和R⁶是氢原子或特定基团、另一个是基团-CO₂R⁴或基团-CONR⁵R⁶，或 R¹ 和 R² 联在一起代表这样形成的五元环，Y 代表特定的基团或原子，X 代表取代或未取代的 C₆-C₁₀ 芳基、C₇-C₁₂ 芳基、杂环或杂环环烷基，m 和 n 代表特定整数，R₃ 代表氢原子、羟基、基团 -OCO₂R⁷、R⁷是氢原子或特定基团，或基团 -OCONR⁸R⁹，R⁸代表 C₁-C₆烷基，R⁹代表氢原子或 C₁-C₆烷基，及其药学上可接受的盐。含有这些衍生物或盐的治疗剂对循环系统疾病有效。